The Bethesda system (TBS) for reporting cervical/vaginal cytological diagnoses was originally developed in 1988 at a National Cancer Institute (NCI) workshop convened to consider the benefits of increased standardization in the diagnostic reports provided by cytology laboratories. 1 It rapidly gained acceptance in laboratory practice in the USA and beyond 2,3 and three years later the NCI sponsored another workshop to assess the use of TBS in practice and consider areas for improvement. 4 Subsequently an illustrated guide was published. 5
Ten years after the publication of the revised Bethesda system, the NCI sponsored another workshop to consider the further development of TBS. The workshop was attended by more than 500 registrants from over 20 countries and was sponsored by 45 professional bodies. The workshop was preceded over six months by a web-based bulletin board covering nine topic areas as described below. Based on the initial bulletin board comments, draft recommendations were drawn up by nominated moderators, revised in the light of further bulletin board comments, and presented for discussion at the workshop.
The first two days of the meeting took the format of presentations from each of nine forum moderators, followed by breakout groups for the relevant sessions. On the concluding day a brief report was given by each of the moderators who incorporated discussions from their breakout groups. The final version of Bethesda 2001 has now been agreed and published on the web. 7 The nine forum groups addressed the following topics: specimen adequacy; benign cellular changes and infections; LSIL/HSIL; ASCUS; AGUS; endometrial cells; HPV triage; computer-assisted diagnosis; recommendations, educational notes and disclaimers.
SPECIMEN ADEQUACY
It was agreed to maintain the satisfactory and unsatisfactory categories as currently defined, but drop the 'Satisfactory but limited by….' category which was felt to be unhelpful and an oxymoron. The unsatisfactory category includes both specimens that are rejected and specimens that are fully evaluated and appropriate terminology has been suggested to allow clarification of the unsatisfactory category e.g. 'Specimen rejected (not processed) because slide broken, specimen not labelled, etc' as opposed to 'Specimen processed and examined, but unsatisfactory for evaluation of epithelial abnormality because of obscuring blood, inflammatory cells, poor fixation, etc'. Additional comments and recommendations can be made as appropriate to provide information on the meaning of specimen limitations and implications for patient followup, and a quality statement related to the presence of indicators of transformation zone sampling.
An example report might read: Negative for intraepithelial lesion or malignancy Satisfactory for evaluation. TZ component present. Assessment of smear cellularity was also discussed. It was accepted for conventional smears that the current recommendation in TBS that 'well-preserved and well-visualized squamous epithelial cells should cover > 10% of slide surface' was subject to differing interpretation: 8, 9 it was suggested that TBS move to a numerical assessment of cellularity defined as a content of 8,000-12 000 well-preserved and well-visualized squamous cells. It was recognized that some cases with cell clustering, atrophy or cytolysis are difficult to estimate and laboratories were recommended to apply professional judgement and employ hierarchical review in the assessment of cellularity in such cases. Counting of individual cells is clearly impractical and simple mechanisms were provided for the rapid estimation of cellularity by use of comparison charts. 7 Since liquid-based cytology (LBC) preparations distribute a random subsample of cells over a circumscribed area an accurate estimate of the cellularity of the preparation can be easily determined in scantily cellular specimens. Preliminary data suggests 5000 well-preserved, well-visualized squamous cells are adequate and this applies to all the currently available LBC systems. A minimum of 10 fields should be counted along a diameter across the centre of the preparation and tables were provided for the average number of cells per microscopic field corresponding to particular cell counts. 7 Cases with fewer than 5000 cells should be examined to determine if the scant cellularity is due to technical problems in preparation of the slide. In such circumstances, a repeat preparation may yield an adequate cellular preparation.
It was recommended that the presence or absence of a transformation zone (TZ) component, defined as at least 10 well-preserved endocervical or squamous metaplastic cells singly or in groups, should be reported in the specimen adequacy section as a quality indicator, except if the specimen shows a high-grade lesion or cancer when it is not necessary to report the presence or absence of a TZ component. Parabasal type cells should not be used as an indicator of TZ sampling, particularly since it may be difficult to distinguish them from squamous metaplastic cells in atrophic smears. In cases in which the TZ component is lacking or insufficient or uncertain, laboratories may make a comment about the significance of a TZ component or the difficulty in determining its presence in the presence of hormonal changes such as atrophy.
There was no change in the criteria for inadequacy due to obscuring factors, which should be applied to both conventional and liquid-based preparations. Specimens with more than 75% of cells obscured should be termed unsatisfactory, and those with 50-75% of cells obscured should be described as partially obscured.
BENIGN CELLULAR CHANGES AND INFECTIONS
It was agreed that the categories of benign cellular changes (BCC) and within normal limits (WNL) should be discontinued and included in a single negative category similar to current British practice. This single negative category would be reported as 'negative for intraepithelial lesion or malignancy'. The option to include reactive and other nonneoplastic changes in the general specimen category was retained although 'atrophy associated inflammation' was dropped from the list of accepted reactive changes. The phraseology used to suggest the presence of bacterial vaginosis was reworded from 'predominance of coccobacilli consistent with shift in vaginal flora' to 'shift in bacterial flora suggestive of bacterial vaginosis'.
LSIL/HSIL
There was no enthusiasm or compelling evidence to return to a three-grade system as used in the UK: squamous epithelial abnormality terminology would remain as originally formulated in TBS. 1, 4 This view was based on the fact that there continues to be a strong biological justification for a two-tiered LSIL/HSIL terminology in which the dividing line is placed between CIN 1 and CIN 2. [10] [11] [12] [13] Furthermore national and international management guidelines based on LSIL and HSIL cytological results have been adopted and clinical practice has successfully adapted to the current LSIL/HSIL terminology.
The recommended terminology for cytological changes suggestive of the presence of invasive squamous carcinoma would be 'HSIL with features suspicious for invasion'.
ASCUS
A strong consensus was developed that there is insufficient evidence in the USA to recommend elimination of an equivocal cytological category by increasing or decreasing the interpretation based on morphology: the current definition of ASCUS emphasizes exclusion criteria rather than what should be included in the category. The poor reproducibility of current ASCUS interpretations provided the basis for recommending a simplified system of qualifiers. A new category of Atypical Squamous Cells (ASC) was proposed, defined as 'Cytologic changes suggestive of a squamous intraepithelial lesion that are quantitatively or qualitatively insufficient for a definitive interpretation'. It was also recommended that the category of ASCUS favour reactive be eliminated in favour of a dichotomous classification as follows:
Atypical Squamous Cells -Undetermined Significance (ASC-US) for cytologic changes that are suggestive of a squamous intraepithelial lesion but lack criteria for a definitive interpretation. This category includes most cases formerly categorized as ASCUS NOS or ASCUS favour SIL and a minority of cases formerly classified as ASCUS, favour reactive. The category excludes cases suggestive of HSIL. It is anticipated ASC-US will account for over 90-95% of ASC reports in most laboratories.
Atypical Squamous Cells -Cannot Exclude HSIL (ASC-H) for cytological changes that are suggestive of HSIL, but lack criteria for definitive interpretation. There was strong support for the development of this category based on its high positive predictive value for CIN 2 and 3 compared to remaining ASC, even though it was recognized to be poorly reproducible and understood to contain both poorly sampled HSIL and its mimics. Review of the literature indicated that the association with underlying CIN 2 and 3 was lower than for HSIL, but sufficiently higher than for ASC-US to warrant consideration of different management recommendations. It is anticipated ASC-H will account for no more than 10% of all ASC.
It was recommended that quality assurance monitoring of ASC reporting should be performed with separate monitoring of ASC-US and ASC-H reporting if possible. ASC reports should not exceed 5% of total specimens with ASC:SIL ratios not higher than 2:1-3:1 in a general screening population. These guidelines may require further revision for liquid-base cytology (LBC) if the initial data suggesting that ASCUS:SIL ratios are lower with LBC are confirmed in further studies.
GLANDULAR ABNORMALITIES

AGUS
It was recommended that the reporting of atypical glandular cells of undetermined significance be revised as follows:
Endocervical adenocarcinoma in situ (AIS) should be added as a discrete interpretation/ diagnosis, and not included as before in 'AGUS, probably reactive', since previous studies have reported the excellent predictive value and reproducibility of properly applied cytologic criteria for the diagnosis of adenocarcinoma in situ. 14 Atypical glandular/endocervical/endometrial cells should be retained but the qualifier 'of undetermined significance' eliminated to avoid confusion with ASCUS. The qualifier 'favour reactive' should also be eliminated, since numerous studies have demonstrated follow up diagnoses of high grade lesions of any type in 5-39% of such cases, and anecdotal evidence from the website suggested that such an interpretation did not always elicit an appropriate clinical response. However, the qualifier 'favour neoplastic' was retained, whilst recognizing that the cytological criteria for the diagnosis of atypical glandular cells were less reproducible and predictive than for AIS or adenocarcinoma. To highlight the glandular nature of the findings, it was proposed that the general categorization include, in addition to 'Epithelial cell abnormality', the specific cell type i.e. squamous or glandular.
An example report therefore might read: Adequacy Satisfactory for evaluation General category Epithelial cell abnormality, glandular Description/ Interpretation Atypical endocervical cells, favour neoplastic Comment
Origin from an endocervical adenocarcinoma cannot be excluded Recommendations
Colposcopy and endocervical curettage Benign appearing glandular cells in specimens from posthysterectomy patients should be reported and categorized as 'negative for intraepithelial lesion or malignancy': no patient with benign glandular cells posthysterectomy has developed recurrent or de novo neoplasia irrespective of the prior malignancy. [15] [16] [17] 
ENDOMETRIAL CELLS
Consensus was reached on all issues regarding the reporting of benign endometrial cells. Only intact exfoliated endometrial glandular cells have clinical significance. Such cells are not associated with significant pathology in women less than 40 years old 18 and need not be reported in women less than this age. However, endometrial cells should always be reported in women from the age of 40 onward. The rationale for this approach was that the menstrual, drug and full clinical history was often unavailable or inaccurate and published data supports stratification of risk by age, not menstrual history. 19 
HPV TRIAGE
Using human papillomavirus testing as the example, recommendations were made on how ancillary testing might be reported in conjunction with cytology. The results should be reported as positive or negative for HPV DNA of a certain type or class and the laboratory method indicated. The specific HPV types included in the assay may be listed. The HPV test result and cytological findings should be reported simultaneously or if this is not possible the cytological and molecular reports should refer to each other.
Testing for HPV DNA may be useful for triage of women who have an ASCUS diagnosis, [20] [21] [22] but has no utility in triage of LSIL. 23 Two generic models of integrated reporting of cytology and HPV DNA testing for ASCUS triage were discussed at the Bethesda Workshop. The probabilistic model (reporting the HPV test result in conjunction with the ASCUS diagnosis and a statement of risk of underlying HSIL) was favoured over the interpretative model (an integrated final interpretation that reflects both the cytomorphology and HPV status). However it was felt that since there are strengths and weaknesses in both models, additional data are required before an optimal reporting model can be advocated.
COMPUTER-ASSISTED DIAGNOSIS
It is recommended that laboratories should indicate the methodology or instrumentation used in all cervical cytology reports, e.g. conventional, AutoPap, ThinPrep, etc. and it is preferable to include a specific reportable field designated for automated screening. Raw data generated from automated screening devices should not be included in the cytology report.
RECOMMENDATIONS AND EDUCATIONAL NOTES
The use of recommendations for follow up of specific cytological diagnoses is considered appropriate in the following situations: when further procedures would help clarify ambiguous findings; to improve specimen quality following one of limited adequacy; and to identify patients who require further triage and potential subsequent management.
Whilst there was consensus that disclaimer-like notes have no value in relieving a laboratory of any liability related to interpretation of a cervical cytology slide, it was felt that an educational statement that addresses the limitations of cervical cytology might be included in the report at the discretion of the laboratory. The intent of such a statement would be solely to help the clinician consider patient triage and management options.
FUTURE DEVELOPMENT
Following Bethesda 2001, the British Society for Clinical Cytology will hold a Consensus Conference in Manchester on 18-19 March 2002 to discuss the terminology of cervical smear reporting and management. The aim is to provide clearer results for women, to improve concordance with other terminologies and to facilitate consistency with new scientific developments and technologies by revising some aspects of the current BSCC terminology. Further details can be found elsewhere in this edition of Cytopathology.
